Titlebook: Stroke Revisited: Dyslipidemia in Stroke; Seung-Hoon Lee,Min Kyoung Kang Book 2021 The Editor(s) (if applicable) and The Author(s), under

nonsensical

Therapeutic Lifestyle Modificationts, whole grains, and fish intake is recommended. Avoid trans fats and reduce saturated fatty acid intake as much as possible. Reduce dietary simple carbohydrates and replace them with monounsaturated fats or polyunsaturated fats. Avoid added sugar and sugar-sweetened beverages. Limit alcohol use..(

燕麥

Statinsrols. The statins have been used for more than 30?years for the prevention of stroke and coronary artery disease. Their primary mechanism of action is via inhibition of the mevalonate pathway, resulting in a decrease of cholesterol and isoprenoid synthesis. Reduction of cholesterol synthesis enhance

Invertebrate

Kernel

猛然一拉

Fish Oils are the essential PUFAs found in fish oil. Early epidemiologic researches have shown a reverse relationship between fish consumption and the risk of coronary heart disease. Since then, several experimental investigations and clinical studies have demonstrated the advantages of fish oil supplementat

companion

PCSK9 Inhibiting Monoclonal Antibodiestroke and TIAs. The current guidelines recommend the use of lipid-lowering medications to reduce the risk of stroke among patients with ischemic stroke or TIA presumed to be of atherosclerotic origin. Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, in addition to healt

TAP

PCSK9 Inhibiting siRNAtilized of all therapies. However, patients who do not respond to statin therapy or other oral agents, or who develop side effects from taking the medications often need novel treatments. Inclisiran is a new and novel small interfering RNA compound which inhibits the translation of mRNA for Proprote

ELATE

Understanding of Clinical Practice Guidelines for Dyslipidemialesterol Education Program-Adult Treatment Panel (NCEP-ATP) I in 1988, guidelines from many associations have evolved. ATP I through III and an updated version of ATP III have been released between 1988 and 2004. These guidelines established the core standards of dyslipidemia treatment and have iden

Basal-Ganglia

integrated

Practical Dyslipidemia Management in Stroke-Specific Situationsprevention. Over the past several decades, remarkable developments in controlling dyslipidemia and a distinct decrease in subsequent cardiovascular events (CVD) have been achieved. This monumental change is due to the use of “statins” or “3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors,”